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CORRECTION  The  Journal of Experimental Medicine 
Dr. M. P. Scheid's name was misspelled  in her article that appeared in the October 1982 issue. 
To ensure that her article is properly cited in the future, please replace page 1057 of volume 
156 with this page. 
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There has been much uncertainty regarding the presence, variety, and maturity of 
T  cells in athymic mice. Placental passage of maternal T  cells cannot account for T 
ceils in nu/nu  progeny of nu/nu  parents (1, and unpublished  observations), and there 
is good evidenceoagainst the hypothesis of a  functional thymic rudiment  (2). 
Prothymocytes, which are present equally in athymic and normal mice, are already 
committed to express the thymocyte surface phenotype and can be induced to do so 
by many nonspecific, as well as thymus-related, agents. Thus, nonspecific induction, 
attributable to incidental conditions, such as endemic viral hepatitis  (3), which vary 
from one mouse colony to another,  can explain  some of the inconsistencies  among 
published reports, at least as these concern surface phenotype. 
As regards function, nu/nu splenocytes, cultured under special conditions including 
provision  of interleukin  2  (IL-2)  1  (4),  respond  to  T  cell  mitogens  and  allogeneic 
stimulator  cells  (mixed  leukocyte  culture)  and  can  yield  cloned  lines  of allogeneic 
killer effector cells (5).  It has even been suggested that lack of IL-2 could be the only 
primary deficiency resulting from lack of a  thymus (6). 
In  the  present  study,  we  sought  to  define  the  T  cell  population  of nu/nu  mice, 
specific pathogen free (SPF)  or germ free, in more detail, according to the criteria of 
diversity of Ly sets and expression of the markers TL and Qa-1, and to see how the 
proportions oft  cells expressing these phenotypes may be affected by treatment with 
thymopentin (TP-5), a synthetic pentapeptide fragment of thymopoietin. 
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